• Kyodo News

  • SHARE

Chugai Pharmaceutical Co. on Wednesday raised its estimate of consolidated net profit for the year ending in December to ¥46 billion from the ¥40 billion forecast in February, as the spread of H1N1 strain of influenza has boosted sales of Tamiflu.

The sales of the flu medicine are expected to soar nearly eightfold from a year earlier to an all-time high of ¥64.9 billion amid a sharp increase in H1N1 flu patients, up from ¥53.0 billion in the previous estimate, according to the company.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW